[go: up one dir, main page]

MA25876A1 - Inhibiteurs tricycliques de poly (adp-ribose) polymerases - Google Patents

Inhibiteurs tricycliques de poly (adp-ribose) polymerases

Info

Publication number
MA25876A1
MA25876A1 MA26577A MA26577A MA25876A1 MA 25876 A1 MA25876 A1 MA 25876A1 MA 26577 A MA26577 A MA 26577A MA 26577 A MA26577 A MA 26577A MA 25876 A1 MA25876 A1 MA 25876A1
Authority
MA
Morocco
Prior art keywords
ribosis
polymerases
adp
tricyclic
inhibitors
Prior art date
Application number
MA26577A
Other languages
English (en)
Inventor
Evan Webber Stephen
James Skalitzky Donald
Girish Tikhe Jayashree
Arnold Kumpf Robert
Timothy Marakovits Joseph
Walter Eastman Brian
Original Assignee
Agouron Pharma
Cancer Res Compaign Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Res Compaign Technology filed Critical Agouron Pharma
Publication of MA25876A1 publication Critical patent/MA25876A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA26577A 1999-08-31 2002-03-29 Inhibiteurs tricycliques de poly (adp-ribose) polymerases MA25876A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
MA25876A1 true MA25876A1 (fr) 2003-10-01

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26577A MA25876A1 (fr) 1999-08-31 2002-03-29 Inhibiteurs tricycliques de poly (adp-ribose) polymerases

Country Status (48)

Country Link
US (1) US6548494B1 (fr)
EP (1) EP1208104B1 (fr)
JP (1) JP4272375B2 (fr)
KR (1) KR20020038742A (fr)
CN (1) CN1384835A (fr)
AP (1) AP1553A (fr)
AR (1) AR035162A1 (fr)
AT (1) ATE287406T1 (fr)
AU (1) AU781826B2 (fr)
BG (1) BG106562A (fr)
BR (1) BR0015051A (fr)
CA (1) CA2382404C (fr)
CO (1) CO5200769A1 (fr)
CR (1) CR6577A (fr)
CZ (1) CZ2002613A3 (fr)
DE (1) DE60017575T2 (fr)
DK (1) DK1208104T3 (fr)
DO (1) DOP2000000069A (fr)
DZ (1) DZ3216A1 (fr)
EA (1) EA200200306A1 (fr)
EC (1) ECSP003637A (fr)
EE (1) EE200200100A (fr)
ES (1) ES2234657T3 (fr)
GE (1) GEP20043268B (fr)
GT (1) GT200000145A (fr)
HK (1) HK1045509B (fr)
HR (1) HRP20020271A2 (fr)
HU (1) HUP0202703A3 (fr)
IL (1) IL147863A0 (fr)
IS (1) IS6289A (fr)
MA (1) MA25876A1 (fr)
MX (1) MXPA02002138A (fr)
MY (1) MY135910A (fr)
NO (1) NO322475B1 (fr)
NZ (1) NZ516793A (fr)
OA (1) OA12016A (fr)
PA (1) PA8501801A1 (fr)
PE (1) PE20010538A1 (fr)
PL (1) PL354242A1 (fr)
PT (1) PT1208104E (fr)
SI (1) SI1208104T1 (fr)
SK (1) SK2592002A3 (fr)
SV (1) SV2003000162A (fr)
UA (1) UA73144C2 (fr)
UY (1) UY26323A1 (fr)
WO (1) WO2001016136A2 (fr)
YU (1) YU15102A (fr)
ZA (1) ZA200200830B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO2001023390A2 (fr) * 1999-09-28 2001-04-05 Basf Aktiengesellschaft Derives d'azepinoindol, preparation et utilisation desdits derives
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
AU2003236686A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors
PT1585749E (pt) 2003-01-09 2008-10-23 Pfizer Derivados de diazepinoindole como inibidores de cinase
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
PT1660095E (pt) * 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (fr) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Composes a anneau bicyclique heterocyclique et a anneau tricyclique heterocyclique et medicaments les contenant
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
WO2006033003A1 (fr) * 2004-09-22 2006-03-30 Pfizer, Inc. Procede de preparation d'inhibiteurs de poly(adp-ribose) polymerases
JP5201995B2 (ja) * 2005-01-19 2013-06-05 エーザイ インク． ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法
US7812013B2 (en) 2005-06-14 2010-10-12 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
EP1908481A1 (fr) 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent pour réduire le saignement lors de troubles cérébrovasculaires
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
AU2006279034A1 (en) * 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP2038654A4 (fr) * 2006-06-12 2010-08-11 Bipar Sciences Inc Procédé permettant de traiter des maladies avec des inhibiteurs de parp
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662517A1 (fr) * 2006-09-05 2008-03-13 Jerome Moore Traitement du cancer
CA2662337A1 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthese d'acides gras au moyen d'inhibiteurs parp et methodes de traitement associees
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154129A1 (fr) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Compositions pharmaceutiques et procédé permettant de traiter, réduire, améliorer, atténuer, ou prévenir la sécheresse oculaire
WO2009034326A1 (fr) 2007-09-14 2009-03-19 Astrazeneca Ab Dérivés de phtalazinone
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
KR20100102637A (ko) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
DK2346495T4 (da) 2008-10-07 2023-08-28 Kudos Pharm Ltd Farmaceutisk formulering 514
WO2011058367A2 (fr) 2009-11-13 2011-05-19 Astrazeneca Ab Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
WO2014037313A1 (fr) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Utilisation de benzodiazepinones et de benzazepinones substituées ou de leurs sels comme principes actifs contre le stress abiotique des plantes
CA2935857C (fr) * 2014-01-05 2020-12-15 Washington University Traceurs radiomarques pour la poly (adp-ribose) polymerase-1 (parp-1), leurs procedes et utilisations
SI3325623T1 (sl) 2015-07-23 2019-11-29 Inst Curie Uporaba kombinacije molekule DBAIT in inhibitorjev PARP za zdravljenje raka
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (fr) 2016-07-28 2018-02-01 Mitobridge, Inc. Méthode de traitement de lésions rénales aiguës.
JP2020500214A (ja) 2016-11-02 2020-01-09 イミュノジェン・インコーポレーテッド 抗体薬物複合体とｐａｒｐ阻害剤との併用治療
WO2018162439A1 (fr) 2017-03-08 2018-09-13 Onxeo Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
CA3092779A1 (fr) 2018-03-13 2019-09-19 Onxeo Molecule dbait contre la resistance acquise dans le traitement du cancer
TW202019408A (zh) * 2018-06-28 2020-06-01 美商永恒生物科技公司 稠合三環雜環化合物及其治療用途
US20240287093A1 (en) * 2018-08-24 2024-08-29 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
US20220144850A1 (en) * 2019-02-02 2022-05-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analogue as parp inhibitor
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CA3146560A1 (fr) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Conjugues peptidiques de cytotoxines servant d'agents therapeutiques
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
AU2021262569A1 (en) 2020-04-28 2022-11-24 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
WO2022090938A1 (fr) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Dérivés de phtalazinone utiles en tant qu'inhibiteurs de parp
PE20240119A1 (es) 2021-01-08 2024-01-22 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados
WO2022155172A1 (fr) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Conjugués peptidiques d'agents thérapeutiques
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors
CA3250650A1 (fr) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill Composés d'arylbenzoisoxazole utilisés en tant qu'inhibiteurs d'ip6k et d'ipmk et leurs procédés d'utilisation
WO2024261243A1 (fr) 2023-06-21 2024-12-26 Hemispherian As Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr
WO2025106920A1 (fr) * 2023-11-15 2025-05-22 Yale University Agents d'imagerie tep de parp et leurs procédés d'utilisation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (fr) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CA2150345A1 (fr) 1993-09-28 1995-04-06 Makoto Komatsu Derives de quinoxaline utilises comme agents antidiabetiques
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
CA2225465A1 (fr) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Composes benzimidazole
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
CN1198614C (zh) 1997-05-13 2005-04-27 奥科特默股份有限公司 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
CA2332239A1 (fr) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Composes condenses tricycliques inhibant l'activite de type poly(adp-ribose) polymerase (parp)

Also Published As

Publication number Publication date
GEP20043268B (en) 2004-06-25
HRP20020271A2 (en) 2005-12-31
CO5200769A1 (es) 2002-09-27
AU7338900A (en) 2001-03-26
CZ2002613A3 (cs) 2002-08-14
CN1384835A (zh) 2002-12-11
IS6289A (is) 2002-02-27
ES2234657T3 (es) 2005-07-01
DK1208104T3 (da) 2005-05-02
SI1208104T1 (en) 2005-06-30
NO322475B1 (no) 2006-10-09
UY26323A1 (es) 2001-04-30
AU781826B2 (en) 2005-06-16
PT1208104E (pt) 2005-04-29
DE60017575D1 (de) 2005-02-24
NZ516793A (en) 2004-03-26
ZA200200830B (en) 2003-03-26
CA2382404A1 (fr) 2001-03-08
IL147863A0 (en) 2002-08-14
PA8501801A1 (es) 2002-08-26
SK2592002A3 (en) 2002-10-08
EP1208104A2 (fr) 2002-05-29
WO2001016136A3 (fr) 2001-06-21
MY135910A (en) 2008-07-31
HUP0202703A3 (en) 2004-12-28
BG106562A (bg) 2003-03-31
AP1553A (en) 2006-01-18
ECSP003637A (es) 2002-03-25
DZ3216A1 (fr) 2001-03-08
AR035162A1 (es) 2004-05-05
SV2003000162A (es) 2003-07-29
DE60017575T2 (de) 2005-06-09
YU15102A (sh) 2004-12-31
NO20020421D0 (no) 2002-01-28
ATE287406T1 (de) 2005-02-15
BR0015051A (pt) 2002-06-25
DOP2000000069A (es) 2002-08-30
OA12016A (en) 2006-04-19
JP4272375B2 (ja) 2009-06-03
EA200200306A1 (ru) 2002-08-29
HUP0202703A2 (hu) 2002-12-28
CR6577A (es) 2003-12-05
EP1208104B1 (fr) 2005-01-19
WO2001016136B1 (fr) 2001-11-15
CA2382404C (fr) 2009-03-24
EE200200100A (et) 2003-06-16
HK1045509B (en) 2005-04-29
MXPA02002138A (es) 2003-08-20
PE20010538A1 (es) 2001-05-22
PL354242A1 (en) 2003-12-29
GT200000145A (es) 2002-02-21
KR20020038742A (ko) 2002-05-23
UA73144C2 (en) 2005-06-15
HK1045509A1 (en) 2002-11-29
NO20020421L (no) 2002-04-25
US6548494B1 (en) 2003-04-15
WO2001016136A2 (fr) 2001-03-08
JP2003513015A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
DZ3216A1 (fr) Inhibiteurs tricycliques de poly(adp-ribose) polymerases
EE200100364A (et) Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid
DK1224174T3 (da) Benzodiazepinderivater
NO20021691D0 (no) Benzodiazepinderivater
NO20016334L (no) Boresystem
ID30132A (id) Turunan-turunan pirazol trisiklik
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
ATE217604T1 (de) Zapfhahn
PT1194404E (pt) Inibidores de aspartil-protease
DE60044611D1 (de) Alicyclisches kohlenwasserstoffcopolymer
DE60026995D1 (de) Nukleierungsmittel
DE50011953D1 (de) Bohrwerkzeug
DE50011611D1 (de) Bohrwerkzeug
BR0013140B1 (pt) conjunto de maÇaneta.
DE69918938D1 (de) Schlüsseleinführungsvorrichtung
DE60028701D1 (de) Synchronisiereinrichtung
DE50011494D1 (de) Bohrwerkzeug
AT3192U3 (de) Raumumschliessender bauteil
MA26795A1 (fr) Analgesiques tricycliques.
DE10085310T1 (de) Schloß
ATE259816T1 (de) Tricyclische benzoylcyclohexandion-derivate
FI990185A0 (fi) Rotaattori
DE60035019D1 (de) Synchronisiereinrichtung
DK1090019T3 (da) Adenosinderivater